Clinical Trials Logo

ITCH clinical trials

View clinical trials related to ITCH.

Filter by:

NCT ID: NCT04700007 Completed - Itch Clinical Trials

Evaluation of Peripheral Itch Mechanisms Following Injection of Morphine (Second Sub-Project)

Start date: January 18, 2021
Phase: N/A
Study type: Interventional

The aim of our 2nd sub-project is to clarify if the capsaicin receptor TRPV1 is implicated in the mechanism of morphine-induced mast cell degranulation. Moreover, we also aim to clarify if the mechanism of opioid-induced itch relay on the histaminergic pathway by using the antihistamine (diphenhydramine) to suppress the release of histamine from peripheral mast cells.

NCT ID: NCT04635254 Completed - Pain, Acute Clinical Trials

The Effect of Halophyte-based Cream on Pain and Itch

Start date: November 12, 2020
Phase: N/A
Study type: Interventional

In this study the investigators wish to investigate whether halophyte-based cream applied to the skin can reduce itch applied by means of small needles from the plant mucuna pruriens (also called cowhage) or by histamine (an itch-evoking substance formed in the human body). Further, the investigators wishes to investigate whether long-term application of halophyte-based cream has a pain-relieving effect on heat/cold and pinprick stimulations.

NCT ID: NCT04613102 Withdrawn - Pain Clinical Trials

The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial

Start date: August 1, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

Epidermolysis bullosa (EB) is rare, devastating, and currently incurable genetic blistering disorders characterized by fragility of skin and mucosal membranes. Therapeutic options for EB are limited. Acute and chronic wounds cause pain, itching and infection, altering quality of life and impair wound healing. In absence of a cure, wound care is paramount to alleviate suffering. Anecdotal experience suggest that CBD application alleviates the pain and itching and improves wound healing by controlling the inflammatory process. We propose to undertake a phase II/III study exploring the safety, tolerability and efficacy of topical application of 3% Cannabidiol cream (CBD) on acute and chronic wounds affecting patients with EB. We are doing this trial to determine safety and tolerability of topical CBD cream in a cohort of RDEB patients with chronic wounds (phase II trial), and to evaluate the efficacy and safety of CBD cream in EB with acute and chronic wounds in promoting wound healing, decrease blister formation, pain, itching and improve overall quality of life (phase III trial)

NCT ID: NCT04588532 Completed - Itch Clinical Trials

Characterization of BAM8-22 as a New Surrogate Model of Non-histaminergic Itch

Start date: October 1, 2020
Phase: N/A
Study type: Interventional

With this experiment, the experimenter wish to asses if substance BAM8-22 (Bovine Adrenal Medulla) induce non-histaminergic itch.

NCT ID: NCT04554888 Completed - Itch Clinical Trials

Characterization of New Human Models of Non-histaminergic Itch and Their Interaction With the TRPM8 Receptor

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

In this experiment the investigators would like to assess if papain induces an itch sensation comparable to the itch sensation induced by cowhage and to confirm that the mechanism of action of papain follows the non-histaminergic pathway.

NCT ID: NCT04515056 Completed - Itch Clinical Trials

Characterization of New Human Models of Non-histaminergic Itch

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

In this experiment the investigators would like to test a new new human itch model based on papain, and to characterize the sensory quality and temporary aspects of papain skin prick test (SPT) in comparison to the inactivated-cowhage delivery system.

NCT ID: NCT04387851 Completed - Pain Clinical Trials

Learning Mechanisms for Placebo and Nocebo Studies on Somatosensory Sensations: a Systematic Review and Meta-analysis.

Start date: March 1, 2019
Phase:
Study type: Observational

Placebo and nocebo effects are defined as the positive and negative effects occurring after the (supposed) administration of an inert treatment, which, through a given learning process, is believed to have positive or negative effects. The objective of this study is to summarize the available knowledge on experimental inductions of placebo and nocebo effects on somatosensory sensations, specifically pain and itch. The aim isto investigate the extent to which learning processes (such as conditioning and verbal suggestions) induce placebo and nocebo effects on pain and itch in healthy humans. The researchers intent to examine expectancy induction methods for placebo and nocebo effects on somatosensory sensations, describe methodological attributes of the research and propose practical and theoretical implications as well as future directions for research investigating placebo and nocebo effects on somatosensory sensations.

NCT ID: NCT04289038 Completed - Pruritus Clinical Trials

The Efficacy of VR and AR on Pruritus

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The research will be conducted randomly in order to determine the effect of VR and AR on pruritus symptom.

NCT ID: NCT04197440 Not yet recruiting - Itch Clinical Trials

Characterization of Bovine Adrenal Medulla (BAM8-22) as a New Surrogate Model of Non-histaminergic Itch

Start date: January 15, 2020
Phase: N/A
Study type: Interventional

With this experiment, the experimenter wish to create a new model of itch based on the substance BAM8-22 (Bovine Adrenal Medulla), which is found naturally in the human body and which has proved to evoke itch.

NCT ID: NCT04115462 Completed - Itch Clinical Trials

A Relation of Morphine-induced Itch and Pain Processing

Start date: January 15, 2020
Phase: N/A
Study type: Interventional

In This experiment, the investigators would like to test the two following hypotheses regarding the mechanisms by which opioids cause itch: 1. Opioids cause itch by a spinal disinhibition mechanism (central nervous system (CNS) effect). 2. Opioids cause itch through a mast cell-destabilizing effect leading to release of histamine and tryptase in the skin where itch is evoked (peripheral mechanism).